Ursula E.
- Country
- Germany
- Department
- Studiensekretariat Innere Medizin II/Gastroenterologie
Research Overview
- Phase II Open-Label Study of Pembrolizumab and Lenvatinib in Advanced Hepatocellular Carcinoma Refractory to Atezolizumab and Bevacizumab Therapy
- Evaluation of Sequential Versus Up-Front Administration of Durvalumab, Tremelimumab, and Bevacizumab in Non-Resectable Hepatocellular Carcinoma
- Phase IIIb Randomized Multicenter Open-Label Trial of Atezolizumab and Bevacizumab Versus Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
Data & Insights
Has run more than one trial at 42 of 135 partner sites.
Specializations
Liver Cancer Treatment
Specializes in innovative approaches for treating hepatocellular carcinoma (HCC) across various disease stages, with particular emphasis on intermediate and advanced cases.
- Non-resectable HCC management
- Intermediate-stage HCC interventions
- Advanced HCC therapeutic strategies
Focuses on developing treatment pathways for patients who cannot undergo surgical resection.
Immunotherapy Applications
Explores the integration of immunotherapeutic agents in liver cancer treatment, including novel combinations with established therapies.
- Combination immunotherapy protocols
- Immune checkpoint inhibitor treatments
- Adjuvant immunotherapy approaches
Investigates immunotherapy effectiveness in various HCC treatment settings.
Interventional Oncology
Implements advanced local-regional therapeutic approaches in conjunction with systemic treatments for liver cancer.
- Transarterial chemoembolization (TACE)
- Selective internal radiation therapy (SIRT)
- Combined local-systemic approaches
Evaluates innovative combinations of local and systemic treatments for optimal patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.